Lupin gets marketing nod for 'Cefpodoxime Proxetil' in France

New Delhi, Mar 13 (UNI) Drug maker Lupin Ltd today said it has received the marketing approval for generic 'Cefpodoxime Proxetil' 100 mg tablets in France.

Lupin will market the product with its French Regulatory agent Venipharm.

'Cefpodoxime Proxetil' is a cephalosporin antibiotic used to treat a variety of bacterial infections.

''This is the first generic approval in France for 'Cefpodixime Proxetil' and Lupin's first significant approval in Europe. We will work with our partners to ensure launch of this generic upon patent expiry,'' said Lupin Ltd Managing Director Kamal Sharma.

''We expect a number of other such approvals in Europe in the coming months,'' he added.

Lupin's 'Cefpodoxime Proxetil' tablets would be the generic equivalent of Sanofi-Aventis's Orelox tablets.

Sales of Orelox tablets in France are close to euro 75 million as per IMS and the patent expiry is August 2007. The French market is the biggest European market for 'Cefpodoxime Proxetil'.

UNI